About obinutuzumab
Anti-CD20 monoclonal antibody
Used for
- Chronic lymphocytic leukemia, with chlorambucil
- Follicular lymphoma, with chemotherapy or alone in selected cases
Usual adult dose
Usually 1,000 mg by intravenous infusion in treatment cycles; schedules vary by cancer and regimen.
Common side effects
- Infusion reactions
- Low white blood cell or platelet counts
- Infections
- Fatigue, nausea, or diarrhea
Important warnings
- Infusion reactions can be severe, especially with the first dose.
- Can cause serious infections and hepatitis B reactivation.
- Rarely causes progressive multifocal leukoencephalopathy, a serious brain infection.
- Tumor lysis syndrome may occur, especially early in treatment.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for six months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for six months after the last dose.
Interactions
- Live vaccines may cause infection; avoid during treatment and until B-cell recovery.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.